Time frame sensitivity of a point-of-care test to monitor isoniazid adherence in TB treatment Source: Annual Congress 2009 - Diagnostic advances in tuberculosis Year: 2009
Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis Source: Eur Respir J 2014; 43: 1519-1522 Year: 2014
Comparison of genotype MTBDRplus assay for rapid detection of rifampicin and isoniazid resistance with conventional drug susceptibility tests in a tertiary care hospital in India Source: International Congress 2016 – Microbiology: bronchoalveolar lavage (BAL) and PCR Year: 2016
An audit of adherence to antituberculous drugs using a new, rapid, point of care test for isoniazid metabolites Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020
Monoresistance to rifampicin – a problem for treatment results? Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006
Substantial time reduction in diagnosis of Mycobacterium tuberculosis rifampicin and isoniazid resistance by the application of a DNA strip hybridization assay in clinical samples Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Pre-chemotherapy drug sensitivity test for antitubercular drugs in India – is it essential? Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005
The compare of the TB-Biochip oligonucleotide microarray system and bacteriological method for detection of rifampin and isoniazid resistance in mycobacterium tuberculosis Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Higher adverse drug reactions but better completion rate of twelve-dose weekly rifapentine plus isoniazid comparing with nine-month daily isoniazid for latent tuberculosis infection among patients under maintenance dialysis Source: Virtual Congress 2020 – Tuberculosis: part 1 Year: 2020
Evaluation of mycobacteria growth in the presence of combinations of antituberculous drugs using colorimetric method Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004
Rapid oral desensitisation to ethambutol, rifampicin and isoniazid Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009
Usefulness of a new molecular method to detect fluoroquinolones, kanamycin, capreomycin and ethambutol resistance in TB clinical isolates and direct specimens Source: Annual Congress 2010 - Tuberculosis: from bench to bedside Year: 2010
Evaluation of a molecular assay for detection of rifampin and isoniazid resistant mycobacterium tuberculosis in strains and clinical samples Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is “blind” treatment dangerous? Source: Eur Respir J 2011; 37: 1283-1285 Year: 2011
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required? Source: Eur Respir J 2013; 42: 1148-1150 Year: 2013